What Is Modeyso Used For? Modeyso is used to treat a type of recurrent brain cancer known as a diffuse midline glioma with a specific genetic mutation known as histone 3 (H3) K27M. Diffuse midline ...

Diffuse midline glioma (DMG) is a rare form of brain tumor that mostly occurs in children and young adults. It can be highly aggressive and difficult to treat. DMGs form within the central nervous ...

Modeyso is the first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma, targeting both adult and pediatric patients. Clinical trials demonstrated a 22% overall response rate with ...

What Is Modeyso, and Why Does It Matter? Modeyso (dordaviprone) is a new oral medicine that treats a rare and aggressive brain tumor, called diffuse midline glioma (DMG), that has a tumor mutation ...

Dordaviprone is the first FDA-approved therapy for recurrent H3 K27M-mutant diffuse midline glioma, targeting an ultra-rare brain tumor in children and young adults. The approval was based on a 22% ...

Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

The US Food and Drug Administration (FDA) has given accelerated approval to Jazz Pharmaceuticals for Modeyso (dordaviprone) to treat adults and paediatric patients aged one year and older with diffuse ...

Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

The FDA has granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals) for H3 K27M-mutant diffuse glioma, marking the first time a systemic therapy has been approved for the ...